Oops! It appears that you have disabled your Javascript. In order for you to see this page as it is meant to appear, we ask that you please re-enable your Javascript!
Analysis of Geographic Breadth on Enr...
Home  »  Community News  »  Analysis of Geograph...
Analysis of Geographic Breadth on Enrollment in Clinical Trials Early-Released at Partnerships in Clinical Trials Europe Conference
Pharma News

HAMBURG, Germany, November 19, 2015 /PRNewswire/ —

Partnerships in Clinical Trials is produced by Informa; 17-19 November, 2015; Hamburg Germany; http://www.informa-ls.com/event/PCT2015

Informa-the leading provider of intelligence on pharmaceutical industry R&D-has early-released an analyst review of “The Effect of Geographic Breadth on Enrollment in Clinical Trials of High Interest Diseases”, exclusively to attendees at the Partnerships in Clinical Trials Europe (“PCT”) conference in Hamburg, Germany. The report captures and analyzes geographic enrollment trends in top indications including Type 2 Diabetes, Alzheimer’s Disease, Non-Small Cell Lung Cancer, Breast Cancer and Rheumatoid Arthritis.

Partnerships in Clinical Trials Europe attendees, who are receiving the enrollment trends analysis in advance of its November 23 full release, are now the first in the industry to have access to actionable intelligence about potential patient recruitment efficiency based on the number of countries included in a clinical trial.

Projecting timelines and identifying sites are key elements to consider while planning clinical trials. Location matters for targeting the right markets and patient populations, but does the total number of countries included affect enrollment? According to Citeline/Informa analyst Doro Shin, who authored the report, spreading the geography of a trial does appear to aid enrollment overall, but effects are disease dependent.

“There is no one size fits all for the optimal number of countries used in a trial,” said Ms Shin. “Because of the disparity, it is important for pharma companies and CROs to understand the landscape of clinical trials in their competitive spaces, which will help them to plan and budget appropriately.”

Ms. Shin’s analysis was based on data from Trialtrove®, Trialpredict® and BioMedTracker®, industry gold standard pharma competitive intelligence tools which provide an unrivaled level of reliable, relevant data to the global pharmaceutical industry.

According to PCT Conference Director Rosie Bernard, the report provides an additional intelligence edge for Partnerships in Clinical Trials attendees.

“This reports highlights the importance of focusing on both target and actual accruals to achieve goal enrolment,” said Bernard.

“The Effect of Geographic Breadth on Enrollment in Clinical Trials of High Interest Diseases” will be available to the public on November 23, 2015 at https://www.citeline.com/category/whitepapers/


Informa’s pharma business intelligence services provide the world’s most comprehensive source of real-time R&D intelligence for the pharmaceutical industry. Services such as Trialtrove®, Trialpredict® and BioMedTracker®, feature an unmatched data collection of global clinical trials, trial timing and likelihood of approval calculations, drawn from over 30,000 unique sources and analyzed by the industry’s largest team of expert analysts and editors.

For more information: http://www.citeline.com


About Partnerships in Clinical Trials

Now in its 14th year PCT attracts over 1,000 attendees and continues to be the go-to event for the clinical trial industry.

Only the most pressing issues are addressed and this year is packed full of informative content, including real-life case studies on partnering and sourcing strategies, governance and change management.

This year PCT also draws upon the patient centricity movement and how it is affecting CRO and sponsor operating strategy. Other critical topics addressed include:

  • 5 years down the line how will we be running clinical trials?
  • What will be the impact of the new clinical trial regulation?
  • How Ebola clinical trial and regulatory pathways were fast tracked- what can be learnt in terms of rapid product development and setting up such trials?
  • Selecting the best outsourcing model for small to mid-size pharma and biotech companies
  • Re-aligning SOP with RBM: How to do this well

The Informa Partnerships in Clinical Trials annual conference provides a platform to keep appraised of what is going on in outsourcing, whether it is information on new strategic alliances, updates on more mature partnerships or just the considerations of the ever changing environment.

Join us next year!  16th – 17th November 2016, Reed Messe Wien Congress Centre, Vienna, Austria.



SOURCE Informa

Courtesy – Medindia

Leave a reply

You must be logged in to post a comment.